FDA seeks to make masked/de-identified data available
This article was originally published in Scrip
Executive Summary
US regulators are proposing making "de-identified" and "masked" study data derived from applications submitted to the agency available to non-FDA experts and other interested parties for the purpose of generating new knowledge aimed at facilitating innovation in new medical products.